1. Home
  2. EBF vs ALT Comparison

EBF vs ALT Comparison

Compare EBF & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ennis Inc.

EBF

Ennis Inc.

HOLD

Current Price

$21.98

Market Cap

519.5M

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.94

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EBF
ALT
Founded
1909
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.5M
421.5M
IPO Year
1994
2005

Fundamental Metrics

Financial Performance
Metric
EBF
ALT
Price
$21.98
$2.94
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
111.6K
3.8M
Earning Date
04-20-2026
05-08-2026
Dividend Yield
4.85%
N/A
EPS Growth
7.79
25.37
EPS
0.39
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$2.96
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$55.90
N/A
Revenue Growth
N/A
105.00
52 Week Low
$16.30
$2.56
52 Week High
$22.36
$6.44

Technical Indicators

Market Signals
Indicator
EBF
ALT
Relative Strength Index (RSI) 59.34 53.21
Support Level $19.92 $2.65
Resistance Level $22.36 $3.15
Average True Range (ATR) 0.37 0.17
MACD 0.03 0.00
Stochastic Oscillator 74.58 41.07

Price Performance

Historical Comparison
EBF
ALT

About EBF Ennis Inc.

Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialties, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360 Custom LabelsSM, ColorWorx, Enfusion, among others. The company's single reportable segment : Print derives its operating revenues from the manufacturing of mostly custom or semi-custom printed products sold mostly to independent distributors in the United States.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: